Effect of prostacyclin (epoprostenol) on the aggregation of human platelets in whole blood in vitro

A.R. Saniabadi, G.D.O. Lowe, J.J.F. Belch, J.C. Barbenel, C.D. Forbes

    Research output: Contribution to journalArticle

    13 Citations (Scopus)

    Abstract

    Prostacyclin (PGI2) is a potent endogenous inhibitor of platelet aggregation. The effect of PGI2 on platelet aggregation and disaggregation in whole human blood was studied at 37 degrees C in vitro. Aggregation or disaggregation was quantified by counting single platelets using the recently developed Ultra Flo 100 Whole Blood Platelet Counter. Aggregation of platelets in whole blood was induced by arachidonic acid (AA, 400 µM), adenosine 5'-diphosphate (ADP, 10 µM), thrombin (0.1 U/ml) and collagen (1 microgram/ml). At peak aggregation, each aggregating agent induced about a 90% fall in the number of single platelets counted. When whole blood was pre-incubated with PGI2 (0.5-8 nM), it dose dependently inhibited aggregation of platelets induced by all four aggregating agents. Platelet aggregates induced by ADP or thrombin could rapidly be disaggregated by PGI2 added to blood at peak aggregation. Disaggregation of collagen-induced platelet aggregation by PGI2 was slow and minimal and it was completely ineffective in disaggregating AA-induced platelet aggregates. Unlike platelet-rich plasma, which is routinely used to study platelet aggregation, the present whole-blood method allows red and white blood cells to exert their influences on platelet function, and is an important step towards a physiological state for evaluating the effects of pharmacological agents on platelets in whole blood in vitro and ex vivo.

    Original languageEnglish
    Pages (from-to)487-494
    Number of pages8
    JournalHaemostasis
    Volume14
    Issue number6
    DOIs
    Publication statusPublished - 1984

    Fingerprint

    Epoprostenol
    Platelet Aggregation
    Blood Platelets
    Adenosine Diphosphate
    Thrombin
    Collagen
    Platelet-Rich Plasma
    Platelet Aggregation Inhibitors
    Platelet Count
    Arachidonic Acid
    In Vitro Techniques
    Leukocytes
    Erythrocytes
    Pharmacology

    Cite this

    Saniabadi, A.R. ; Lowe, G.D.O. ; Belch, J.J.F. ; Barbenel, J.C. ; Forbes, C.D. / Effect of prostacyclin (epoprostenol) on the aggregation of human platelets in whole blood in vitro. In: Haemostasis. 1984 ; Vol. 14, No. 6. pp. 487-494.
    @article{94302d3846fd42e3b71ddce15049d48e,
    title = "Effect of prostacyclin (epoprostenol) on the aggregation of human platelets in whole blood in vitro",
    abstract = "Prostacyclin (PGI2) is a potent endogenous inhibitor of platelet aggregation. The effect of PGI2 on platelet aggregation and disaggregation in whole human blood was studied at 37 degrees C in vitro. Aggregation or disaggregation was quantified by counting single platelets using the recently developed Ultra Flo 100 Whole Blood Platelet Counter. Aggregation of platelets in whole blood was induced by arachidonic acid (AA, 400 µM), adenosine 5'-diphosphate (ADP, 10 µM), thrombin (0.1 U/ml) and collagen (1 microgram/ml). At peak aggregation, each aggregating agent induced about a 90{\%} fall in the number of single platelets counted. When whole blood was pre-incubated with PGI2 (0.5-8 nM), it dose dependently inhibited aggregation of platelets induced by all four aggregating agents. Platelet aggregates induced by ADP or thrombin could rapidly be disaggregated by PGI2 added to blood at peak aggregation. Disaggregation of collagen-induced platelet aggregation by PGI2 was slow and minimal and it was completely ineffective in disaggregating AA-induced platelet aggregates. Unlike platelet-rich plasma, which is routinely used to study platelet aggregation, the present whole-blood method allows red and white blood cells to exert their influences on platelet function, and is an important step towards a physiological state for evaluating the effects of pharmacological agents on platelets in whole blood in vitro and ex vivo.",
    author = "A.R. Saniabadi and G.D.O. Lowe and J.J.F. Belch and J.C. Barbenel and C.D. Forbes",
    year = "1984",
    doi = "10.1159/000215110",
    language = "English",
    volume = "14",
    pages = "487--494",
    journal = "Haemostasis",
    issn = "0301-0147",
    publisher = "S. Karger AG",
    number = "6",

    }

    Effect of prostacyclin (epoprostenol) on the aggregation of human platelets in whole blood in vitro. / Saniabadi, A.R.; Lowe, G.D.O.; Belch, J.J.F.; Barbenel, J.C.; Forbes, C.D.

    In: Haemostasis, Vol. 14, No. 6, 1984, p. 487-494.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Effect of prostacyclin (epoprostenol) on the aggregation of human platelets in whole blood in vitro

    AU - Saniabadi, A.R.

    AU - Lowe, G.D.O.

    AU - Belch, J.J.F.

    AU - Barbenel, J.C.

    AU - Forbes, C.D.

    PY - 1984

    Y1 - 1984

    N2 - Prostacyclin (PGI2) is a potent endogenous inhibitor of platelet aggregation. The effect of PGI2 on platelet aggregation and disaggregation in whole human blood was studied at 37 degrees C in vitro. Aggregation or disaggregation was quantified by counting single platelets using the recently developed Ultra Flo 100 Whole Blood Platelet Counter. Aggregation of platelets in whole blood was induced by arachidonic acid (AA, 400 µM), adenosine 5'-diphosphate (ADP, 10 µM), thrombin (0.1 U/ml) and collagen (1 microgram/ml). At peak aggregation, each aggregating agent induced about a 90% fall in the number of single platelets counted. When whole blood was pre-incubated with PGI2 (0.5-8 nM), it dose dependently inhibited aggregation of platelets induced by all four aggregating agents. Platelet aggregates induced by ADP or thrombin could rapidly be disaggregated by PGI2 added to blood at peak aggregation. Disaggregation of collagen-induced platelet aggregation by PGI2 was slow and minimal and it was completely ineffective in disaggregating AA-induced platelet aggregates. Unlike platelet-rich plasma, which is routinely used to study platelet aggregation, the present whole-blood method allows red and white blood cells to exert their influences on platelet function, and is an important step towards a physiological state for evaluating the effects of pharmacological agents on platelets in whole blood in vitro and ex vivo.

    AB - Prostacyclin (PGI2) is a potent endogenous inhibitor of platelet aggregation. The effect of PGI2 on platelet aggregation and disaggregation in whole human blood was studied at 37 degrees C in vitro. Aggregation or disaggregation was quantified by counting single platelets using the recently developed Ultra Flo 100 Whole Blood Platelet Counter. Aggregation of platelets in whole blood was induced by arachidonic acid (AA, 400 µM), adenosine 5'-diphosphate (ADP, 10 µM), thrombin (0.1 U/ml) and collagen (1 microgram/ml). At peak aggregation, each aggregating agent induced about a 90% fall in the number of single platelets counted. When whole blood was pre-incubated with PGI2 (0.5-8 nM), it dose dependently inhibited aggregation of platelets induced by all four aggregating agents. Platelet aggregates induced by ADP or thrombin could rapidly be disaggregated by PGI2 added to blood at peak aggregation. Disaggregation of collagen-induced platelet aggregation by PGI2 was slow and minimal and it was completely ineffective in disaggregating AA-induced platelet aggregates. Unlike platelet-rich plasma, which is routinely used to study platelet aggregation, the present whole-blood method allows red and white blood cells to exert their influences on platelet function, and is an important step towards a physiological state for evaluating the effects of pharmacological agents on platelets in whole blood in vitro and ex vivo.

    U2 - 10.1159/000215110

    DO - 10.1159/000215110

    M3 - Article

    VL - 14

    SP - 487

    EP - 494

    JO - Haemostasis

    JF - Haemostasis

    SN - 0301-0147

    IS - 6

    ER -